TradeUp Acquisition, Estrella Biopharma complete business combination

Estrella Immunopharma, formerly known as TradeUP Acquisition Corp. (UPTD), announced the successful closing of its business combination with Estrella Biopharma, a preclinical-stage biopharmaceutical company developing T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. The resulting combined company will operate under the name Estrella Immunopharma, Inc. and will be led by Estrella Founder and CEO Dr. Cheng Liu. The combined company’s common stock and warrants will trade on NASDAQ under the symbols “ESLA,” and “ESLAW,” respectively, effective October 2. On or about October 2, all remaining UPTD units will separate into their underlying components, which consist of one share of combined company’s common stock and one-half of one warrant. Dr. Liu, President and CEO of Estrella, said, “Our anti-CD19 ARTEMIS T-cell therapy has the potential to improve patient outcomes while reducing the risk of Cytokine Release Syndrome. This marks a critical advancement in the management of blood cancer treatments.”